NAPA, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Senetek PLC , a specialty life sciences company engaged in the study of senescense, the science of aging with an initial focus on skincare and dermatological therapeutics, today announced that the Annual General Meeting of Senetek PLC, scheduled for 10:00 a.m. November 12, 2007 at Baker & MacKenzie, London, United Kingdom was adjourned as a result of a lack of a quorum and has been rescheduled to 7:00 a.m. Pacific Time on Monday, December 10, 2007 at the principal executive offices of Senetek PLC, 831A Latour Court, Napa California. The Extraordinary General Meeting of the Company also previously scheduled for November 12, 2007 has also been rescheduled for Monday, December 10, 2007, immediately following the Annual General Meeting.
As of November 12, proxies representing approximately 99.4% of the Company’s voting have been received by the Company. The following table summarizes the voting results to date for each resolution to be considered at the rescheduled Annual General Meeting. Please note that proxy voting instructions may be withdrawn or changed prior to the rescheduled Annual General Meeting and, as result, the following information may not be indicative of the actual final vote tallies that will be reported following the conclusion of the rescheduled Annual General Meeting:
Due to a technical error in proxy solicitation, approximately 200 Ordinary shareholders holding approximately 300,000 shares did not receive notice of the meeting, proxy cards or the proxy statement in relation to the meetings. A revised notice, along with proxy cards and the proxy statement are being sent to these holders of Ordinary shares. Holders who had previously received the notice of meeting and related proxy materials will receive a revised notice of meeting. All votes received by the dates provided in the revised notice of meeting will be tabulated and included in the final vote to be published after the Annual General Meeting on December 10, 2007.
About Senetek PLC
Senetek PLC is a specialty life sciences company engaged in the study of senescense, the science of aging with an initial focus on skincare and dermatological therapeutics. Senetek recently announced a Marketing Collaboration Agreement for its second-generation cytokinin with Triax Aesthetics LLC which will guarantee a minimum of $10.8 million in revenues in 2008 and granted Valeant Pharmaceuticals a paid up license for Senetek’s first generation patented skin care active ingredient Kinetin and its analog Zeatin in return for $21 million cash and forgiveness of $6 million prepaid royalty credit, and is negotiating third party license agreements for new patent-pending second generation dermatological active ingredients and is completing development of a number of additional compounds. In addition, Senetek has entered into exclusive licenses for Europe and North America, respectively, for Invicorp(R), has an exclusive manufacturing distributorship for its proprietary diagnostic monoclonal antibodies, and recently sold, with retained rights of profit participation, its patented drug delivery system, Reliaject(R). For more information, visit the company’s website at http://www.senetekplc.com.
This news release contains statements that may be considered ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
CONTACT: William F. O’Kelly, Chief Financial Officer of Senetek, PLC,
+1-707-226-3900, ext. 102
Web site: http://www.senetekplc.com/
